Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 12/20 | 0.53 |
| ▸ | TOP2A | P11388 | 4/20 | 0.51 |
| ▸ | TOP2B | Q02880 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.47 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.47 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.47 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9838696 | 0.91 | GSK3B (0.58) | GSK3BTOP2ATOP2BMEN1KMT2A | |
| SCHEMBL7046605 | 0.88 | GSK3B (0.51) | GSK3BTOP2ATOP2BMEN1KMT2A | |
| SCHEMBL6878164 | 0.87 | GSK3B (0.40) | GSK3BTOP2ATOP2BMEN1KMT2A | |
| SCHEMBL7046482 | 0.87 | GSK3B (0.40) | GSK3BTOP2ATOP2BMEN1KMT2A | |
| SCHEMBL7111565 | 0.86 | ADRB2 (0.50) | GSK3BTOP2ATOP2BMEN1KMT2A | |
| SCHEMBL8111016 | 0.86 | TOP2A (0.58) | GSK3BTOP2ATOP2BMEN1KMT2A | |
| SCHEMBL7576011 | 0.86 | GSK3B (0.66) | GSK3BTOP2ATOP2BMEN1KMT2A | |
| SCHEMBL500723 | 0.81 | GSK3B (0.66) | GSK3BTOP2ATOP2BMEN1KMT2A | |
| SCHEMBL5868648 | 0.80 | GSK3B (0.60) | GSK3BTOP2ATOP2BMEN1KMT2A | |
| SCHEMBL12674061 | 0.80 | TOP2A (0.67) | GSK3BTOP2ATOP2BMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6825353-B2 | AN AMINE SUBSTITUENT AT THE 7-POSITION OF THE QUINOLONE-CARBOXYLIC ACID DERIVATIVE IS PRODUCED; BACTERICIDES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-11-30 | — | — | US | disclosed |
| US-20030060631-A1 | Process for producing quinolonecarboxlic acids and intermediates thereof | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-03-27 | — | — | US | disclosed |
| EP-1258478-A1 | PROCESS FOR PRODUCING QUINOLONECARBOXYLIC ACIDS AND INTERMEDIATES THEREOF | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2002-11-20 | — | — | EP | disclosed |
| JP-2000247970-A | PRODUCTION OF 5-AMINO-8-METHYL-7-PYPROLIDINYLQUINOLINE-3- CARBOXYLIC ACID DERIVATIVE AND INTERMEDIATE THEREFOR | HOKURIKU SEIYAKU CO LTD | 2000-09-12 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030060631-A1 | Process for producing quinolonecarboxlic acids and intermediates thereof | NQO2, QPCT, QARS1 | GSK3B 1080/4885TOP2A 747/4885TOP2B 785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.